CanSino Biologics (HKG:6185) recorded a net profit attributable to shareholders of 3.0 million yuan for the third quarter of 2024 while the Earnings per share stood at 0.01 yuan for the reporting period, a Tuesday filing with the Hong Kong Exchange said.
The vaccine company's operating revenue for the three months ended Sept. 30 was 263.6 million yuan, 76.09% higher than a year ago.
The company's shares were down nearly 2% on Tuesday's close.
Price (HKD): $26.20, Change: $-0.45, Percent Change: -1.69%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments